We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA TO EVALUATE PROSPECTS FOR CRITICAL PATH RESEARCH
FDA TO EVALUATE PROSPECTS FOR CRITICAL PATH RESEARCH
September 3, 2004
As part of its continuing effort to accelerate drug development, the FDA’s Pharmaceutical Science Advisory Committee will meet Oct. 19 to evaluate research opportunities under the agency’s Critical Path Initiative.